Wainberg, Z. A., Besse, B., Pallis, A. G., Habermehl, C., Kato, K. (2025). PROCEADE PanTumor: A phase 1b/2, multicenter study of precemtabart tocentecan (M9140), an anti-CEACAM5 antibody-drug conjugate (ADC) with exatecan payload, in patients with advanced solid tumors.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.tps3165